Germany | Bayern

Zurück zur Suche

Internationale Partnersuche

Innovation & Technologie Angebot

Licensing Partner sought for new class of Antibiotics effective against common and severe infections

Country of Origin: Germany
Reference Number: TODE20171228001
Publication Date: 9 January 2018


A German University is searching a licensing partner for a newly developed class of Antibiotics against Gram-positive bacteria. Among them are some of the most dangerous pathogens for humans. It can be applied as an antibiotic or as a probiotic. Advantages of this new class are very rapid killing of pathogenic bacteria, low toxicity and an assumed targeting of structures, so far not covered by established antibiotics.


A German Research Group of a University has identified a new class of Antibiotics, showing extraordinary effects in animal models against highly-resistant bacteria, called Gram-positive Bacteria. 
Among Gram-positive bacteria are some of the most dangerous pathogens for humans. Especially Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for a high percentage of hospital-acquired deadly infections, because of its resistance against common Antibiotics. The new found antibiotic class offers the possibility of developing new pharmaceutically applicable antibiotics.
On the other side, the newly identified naturally human-associated bacterial antibiotic producer strain (S. lugdunensis IVK28 wild type) could be applied as a probiotic cure before patients enter hospital. This could avoid costly decolonization of human commensal bacteria before surgery. Also it could replace usual antibiotics and thus reduce the hospitalization duration.
The antibiotic producer strain is applicable in human medicine but also in veterinary medicine against a broad range of Gram-positive bacteria. A patent application covering the chemical structures, the genetic background of the producer strain, the bioactivity of the new substances and their synthesis has been filed.
The University is looking for a licensing partner to take the antibiotic and/or antibiotic producer strain to a new medicine. Ideally this is a pharmaceutical company with experiences in the development of marketable medications.



Advantages and Innovations

- Very rapid killing of pathogenic bacteria even in the non-growing state. Application of 1 microgram/milliliter (MIC) leads to complete killing of bacteria in vitro.
- Efficiency of the pure compound already shown in a topical mouse model
- Low toxicity: First data point to a low cytotoxic potential against human cells.
- Preliminary data suggest, that molecular target might be a biochemical structure so far not targeted by established antibiotics.

Stage Of Development

Prototype available for demonstration

Requested partner

Type of Partner:  Industrial partner
Activity of Partner: Pharmaceutical company
Role of Partner: Licensing of the antibiotic substance for the development of a marketable product.

Kooperationsanfrage stellen